
ASCENTAGE PH.GRP SP.ADR/4
Share · US04390B1052 · AAPG · A40ZYR (XNMS)
27,99 EUR
12.06.2025 17:34
Current Prices from ASCENTAGE PH.GRP SP.ADR/4
Exchange | Ticker | Currency | Last Trade | Price | Daily Change |
---|---|---|---|---|---|
![]() NASDAQ |
AAPG
|
USD
|
12.06.2025 17:34
|
32,13 USD
| 29,75 USD
+8,02 %
|
Performance
Day | Week | Month | 3 Months | 6 Months | 1 Year | 5 Years |
---|---|---|---|---|---|---|
7,56 % | 14,03 % | 27,87 % | 61,21 % | 55,24 % | 60,28 % | 66,85 % |
Company Profile for ASCENTAGE PH.GRP SP.ADR/4 Share
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor; APG-265, a MDM2 protein degrader; and UBX1967/1325, which are Bcl-2 inhibitors. In addition, it is also involved in medical research and development; clinical development; clinical trial operation; venture capital investment; rental services; and science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
Company Data
Name ASCENTAGE PH.GRP SP.ADR/4
Company Ascentage Pharma Group International
Symbol AAPG
Website
https://www.ascentage.cn
Primary Exchange
Frankfurt

WKN A40ZYR
ISIN US04390B1052
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Dr. Dajun Yang M.D., Ph.D.
Market Capitalization 2 Mrd.
Country China
Currency EUR
Employees 0,6 T
Address Suzhou Industrial Park, 215000 Suzhou
IPO Date 2025-01-24
ID Changes
Date | From | To |
---|---|---|
27.01.2025 | AAPGV | AAPG |
Ticker Symbols
Name | Symbol |
---|---|
Frankfurt | 36X0.F |
NASDAQ | AAPG |
More Shares
Investors who ASCENTAGE PH.GRP SP.ADR/4 hold also have the following shares in their portfolio:
The financial platform MoneyPeak tracks and analyzes investments and portfolios.
From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.